220355-63-5
220355-63-5 結(jié)構(gòu)式
基本信息
UKI-1C
1-Piperazinecarboxylic acid, 4-[(2S)-3-[3-(aminoiminomethyl)phenyl]-1-oxo-2-[[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]amino]propyl]-, ethyl ester
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-100415 | 220355-63-5 UKI-1 | 220355-63-5 | 1mg | 1500元 |
| 2026/06/05 | HY-100415 | 220355-63-5 UKI-1 | 220355-63-5 | 5mg | 3500元 |
| 2026/06/05 | HY-100415 | 220355-63-5 UKI-1 | 220355-63-5 | 10mM * 1mLin DMSO | 4726元 |
常見問題列表
Ki: 0.41 μM (Urokinase-type plasminogen activator (uPA))
Serine protease
UKI-1 (WX-UK1; 0.1-1.0 μg/mL) treatment shows a decrease of tumor cell invasion by up to 50% is achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa.
UKI-1 (WX-UK1) interferes with the plasminogen activation system at 2 levels: it inhibits plasmin formation directly and via inhibition of uPA. In vitro invasion models with highly invasive fibrosarcoma and breast cancer cells showed that UKI-1 effectively inhibits migration of the cells through fibrin matrices.
UKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models.